Table 4.
OS | Univariate Cox regression | Multivariable Cox regression | ||
---|---|---|---|---|
| ||||
HR (95% CI) | p value | HR (95% CI) | p value | |
Heng prognostic group | ||||
Good vs. poor | 0.15 (0.07–0.31) | <0.001 | 0.17 (0.08–0.37) | <0.001 |
Intermediate vs. poor | 0.28 (0.16–0.53) | <0.001 | 0.27 (0.15–0.50) | <0.001 |
BM (Y/N) | 1.84 (1.25–2.72) | 0.002 | 1.81 (1.21–2.70) | 0.003 |
Sites of metastases ≥ 2 (Y/N) | 1.72 (0.92–3.23) | 0.088 | ||
Therapy (SO vs. EV) | 2.43 (1.65–3.63) | <0.001 | 2.21 (1.47–3.31) | <0.001 |
OS: overall survival; BM: bone metastases, CI: confidence interval; HR: hazard ratio; Y: yes; N: no; EV: everolimus; SO: sorafenib.